Article

<i>TP53</i> mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance

2018-08-30

Abstract excerpt

<h4>Background:</h4> MDM2 inhibitors are under investigation for the treatment of acute myeloid leukaemia (AML) patients in phase III clinical trials. To study resistance formation to MDM2 inhibitors in AML cells, we here established 45 sub-lines of the AML TP53 wild-type cell lines MV4-11 (15 sub-lines), OCI-AML-2 (10 sub-lines), OCI-AML-3 (12 sub-lines), and SIG-M5 (8 sub-lines) with resistance to the MDM2 inh...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 63a82ebd-aa60-5397-aee4-b26fd7416eb4
DOI: 10.1101/404475

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>TP53</i> mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistanceDOI 10.1101/404475Read

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?Semantic proximity Read

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemiaSemantic proximity Read

<i>TP53</i> Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid LeukemiaSemantic proximity Read

Towards the overcoming of anticancer drug resistance mediated by p53 mutations.Semantic proximity Read

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockadeSemantic proximity Read

High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemiaSemantic proximity Read

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance MechanismsSemantic proximity Read

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.Semantic proximity Read

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe RevisitedSemantic proximity Read

AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.Semantic proximity Read

Identifying the determinants of response to MDM2 inhibitionSemantic proximity Read

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML CellsSemantic proximity Read